Table 1.
Patient and Facility Characteristics in Etelcalcetide-First Versus Cinacalcet-First HD Facilities
| Characteristics | Cinacalcet-First (n = 1,187) | Etelcalcetide-First (n = 969) |
|---|---|---|
| N facilities | 67 | 45 |
| Demographics | ||
| Age (y) | 59 ± 14 | 64 ± 14 |
| Sex (% male) | 56% | 56% |
| Race (% Black) | 45% | 36% |
| Dialysis vintage (y) | 4.7 (2.6-7.8) | 3.6 (1.8-7.0) |
| Body mass index (kg/m2) | 29.6 ± 7.7 | 30.6 ± 7.9 |
| Comorbid history (%) | ||
| Coronary artery disease | 27% | 23% |
| Cerebrovascular disease | 7% | 9% |
| Heart failure | 20% | 24% |
| Peripheral vascular disease | 15% | 11% |
| Hypertension | 92% | 81% |
| Other cardiovascular disease | 14% | 25% |
| Cancer (nonskin) | 5% | 5% |
| Diabetes | 63% | 62% |
| Gastrointestinal bleeding | 6% | 7% |
| Lung disease | 5% | 8% |
| Neurologic disease | 9% | 4% |
| Psychiatric disorder | 26% | 27% |
| Recurrent cellulitis, gangrene | 9% | 6% |
| Markers of nutrition and inflammation | ||
| Serum albumin (g/dL) | 3.9 ± 0.3 | 3.8 ± 0.3 |
| Hemoglobin (g/dL) | 10.8 ± 1.0 | 10.7 ± 1.1 |
| Serum potassium (mEq/L) | 4.8 ± 0.5 | 4.7 ± 0.5 |
| Dialysis treatments | ||
| Catheter use (%) | 10% | 17% |
| Facility-level characteristics | ||
| Dialysis organization size (% LDO/MDO vs SDO/Ind) | 78% | 14% |
| Facility size (N patients) | 87 ± 40 | 73 ± 31 |
| Facility % Black race | 38 ± 30 | 32 ± 30 |
| Facility % calcimimetic use | 29 ± 10 | 43 ± 17 |
| Facility % vitamin D use | 82 ± 9 | 66 ± 14 |
| Facility % phosphate binder (calcium-based) use | 47 ± 28 | 52 ± 23 |
| Facility % phosphate binder (non–calcium-based) use | 47 ± 22 | 49 ± 21 |
| Facility mean dialysate calcium (mEq/L) | 2.5 ± 0.1 | 2.6 ± 0.2 |
| Facility type (% hospital-based) | 4% | 28% |
| Facility location (% rural) | 19% | 8% |
Note: Results are shown as mean ± standard deviation, median (interquartile range), or percentage. The proportion with missing data was <2% for all variables, except for Black race (14%) and dialysis vintage (7%).
Abbreviations: HD, hemodialysis; Ind, independent HD units; LDO/MDO, large/medium dialysis organizations with 10+ affiliated HD units; SDO, small dialysis organizations (<10 affiliated units).